Results 61 to 70 of about 8,600 (158)

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

BMC Musculoskeletal Disorders, 2012
Background This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP).
Murphy Daniel R, Smolen Lee J, Klein Timothy M, Klein Robert W   +3 more
doaj   +1 more source

A randomized controlled trial of teriparatide for accelerating bone union and improving clinical outcomes in patients with pertrochanteric fracture fixation

Scientific Reports
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Chotetawan Tanavalee, Srihatach Ngarmukos, Chavarin Amarase, Saran Tantavisut, Nonn Jaruthien, Aree Tanavalee   +5 more
doaj   +1 more source

No effect of teriparatide on migration in total knee replacement: A randomized controlled trial involving 50 patients

Acta Orthopaedica, 2017
Background and purpose — Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans.
Håkan Ledin, Lars Good, Torsten Johansson, Per Aspenberg   +3 more
doaj   +1 more source

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis

Therapeutics and Clinical Risk Management, 2010
Arthur N Lau, Jonathan D AdachiDivision of Rheumatology and Department of Medicine, St Joseph’s Healthcare and McMaster University, Hamilton, Ontario, CanadaAbstract: Glucocorticoids are commonly used in various fields within medicine.
Arthur N Lau, Jonathan D Adachi
doaj  

Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis

Frontiers in Pharmacology
Background: Several medications have been used for glucocorticoids-induced osteoporosis (GIO). However, the best therapeutic option for GIO is still controversial.
Liang Dong, Lianghai Jiang, Zhengwei Xu, Xiaobo Zhang   +3 more
doaj   +1 more source

Teriparatide mitigates oxidative stress following spinal cord injury and enhances neurological recovery via the Nrf2/HO-1 signaling pathway

Frontiers in Pharmacology
IntroductionSpinal Cord Injury (SCI) represents a devastating form of central nervous system trauma, where oxidative stress plays a critical role in the ensuing pathology. Targeting oxidative stress presents a viable therapeutic avenue.
Xiong Moliang, Ai Gangtong, Feng Yun, Luo Caiguang, Deng Liang, Guo Jia, Xiao Qiang   +6 more
doaj   +1 more source

Weekly Injection of Teriparatide for Bone Ingrowth after Cementless Total Knee Arthroplasty

Journal of Orthopaedic Surgery, 2016
Purpose. To compare bone mineral density (BMD) in patients with or without weekly injection of teriparatide to promote bone ingrowth after cementless total knee arthroplasty (TKA). Methods.
Takao Kaneko, Takahiro Otani, Norihiko Kono, Yuta Mochizuki, Takeo Mori, Nobuhito Nango, Hiroyasu Ikegami, Yoshiro Musha   +7 more
doaj   +1 more source

Low Rate of Teriparatide Supplementation for the Treatment of Osteoporotic Pelvic Fractures in Elderly Females

Geriatric Orthopaedic Surgery & Rehabilitation
Background Osteoporotic pelvic fractures in the elderly lead to pain and immobility resulting in decreased quality of life and worsening frailty. Teriparatide has been shown to shorten time to fracture union, diminish pain, and improve mobilization.
David Novikov MD, Mary Grace Kelley MS, Michael S. Kain MD, Paul Tornetta MD, PhD   +3 more
doaj   +1 more source

Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation

Clinical Interventions in Aging, 2015
Takanori Yamamoto,1 Mika Tsujimoto,2 Hideaki Sowa11Medical Science, Lilly Research Laboratories, Medicines Development Unit Japan, 2Asia Pacific Statistical Science-Japan, Science and Regulatory Affairs, LRL MDU-Japan, Eli Lilly Japan K.K, Kobe, Hyogo ...
Yamamoto T, Tsujimoto M, Sowa H
doaj  

Mechanisms limiting the long-term anabolic effects of teriparatide (PTH 1-34) on bone. [PDF]

JBMR Plus
Schmal C, Wu JY, Jafari A.
europepmc   +1 more source